SAN DIEGO, Calif. — Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for conversion of the existing U.S. accelerated approval of FILSPARI® (sparsentan) in IgA nephropathy (IgAN) to full approval. In February 2023, the...
Latest News
San Diego, Calif. – Travere Therapeutics on Friday released more data from the Phase III PROTECT and DUPLEX studies—in IgA nephropathy and focal segmental glomerulosclerosis, respectively—showing that treatment with Filspari (sparsentan) can preserve kidney function in these diseases. The results were presented at the American Society of Nephrology’s Kidney Week...
A pilot study by a team of multiple sclerosis (MS) researchers showed that treadmill walking exercise training may be an effective approach to managing the debilitating cognitive effects of the disease. Their article, titled, “Effects of walking exercise training on learning and memory and hippocampal neuroimaging outcomes in MS: A...
TORONTO, Ontario & SAN FRANCISCO, Calif. — Treadwell Therapeutics, a privately held clinical-stage biotechnology company pioneering and advancing novel first-in-class medicines for unmet needs in cancer, today announced the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ocifisertib (CFI-400945), a first-in-class, investigational PLK4 inhibitor for the...
Cologne, Germany – In cooperation with research partners in Germany and France, the infectious disease specialist Dr Jan Rybniker and his team at University Hospital Cologne and the University of Cologne’s Faculty of Medicine have identified new, antibiotic molecules that target Mycobacterium tuberculosis and make it less pathogenic for humans....
Paris, France – A protein found abundantly in breast cancers that are refractory to conventional treatments is thought to cause the development of metastasis. Targeting it would prevent metastatic spread and therefore increase patients survival. These are the findings of a study conducted by a French-American team and led by...
A wave of new therapies is starting to reshape the treatment landscape for people with rare anemias, but the authors of a new review also caution that more research is needed to better understand which therapies are right for which patients. Writing in Frontiers in Medicine, the authors began by...
Beijing, China – Lung cancer is the leading cause of cancer-related death worldwide. Improved understanding of driver mutations of non-small cell lung cancer (NSCLC) has led to more biomarker-directed treatment for patients with advanced stages. The expanding number of drugs targeting these driver mutations offers more opportunity to improve patient’s...
Niigata, Japan – A new Japanese nationwide study revealed that from 2006 to 2021, the number of patients with incident renal RRT due to RPGN increased, with an increase in the age-specific incidence of RRT due to RPGN in the older age groups (≥70 years old). Given the increasing trend...
Atlanta – In a post hoc analysis of the phase 2 NOBILITY trial, researchers found that treatment with obinutuzumab—an antibody that targets a protein expressed on certain immune cells—was superior to placebo for preserving kidney function and preventing flares in patients with lupus nephritis, a kidney condition associated with the...